Full text of accepted abstracts will be made available to registrants on the first day of the Congress at 8:00am BST. Researchers and presenters are free to discuss the content of their abstracts throughout this embargo period, but any abstract-related content may not be published until the abstracts are publicly released online.
Updated data, new graphics, and follow-up information to be presented during oral presentation sessions is embargoed until 8:00am BST on the day of the presentation.
Posters will be made available from the first day of the Congress, therefore all updated data, new graphics, and follow-up information is embargoed until 8:00am BST on the first day of the Congress.
In exceedingly rare circumstances, ESGCT may grant an exception to the embargo policy in order to comply with regulations from the ESMA or international law.
Any exception request must be submitted to ESGCT in writing to Gaëlle Jamar at least 72 hours before the conclusion of the public embargo, and must include the following:
Statement that an exception is required to abide by applicable securities laws
Statement that the disclosed information is the absolute minimum necessary to comply with the applicable securities law
The lead author and presenter (both if they are different) copied on any correspondence
Signature of legal counsel
Whenever possible, ESGCT prefers any disclosure to follow these guidelines:
Do not include implications or translational interpretations of results
Necessary data presented in qualitative terms rather than quantitative terms
Include the submission to and upcoming presentation at the ESGCT congress
For example, a press release stating “the research which will be presented at the ESGCT conference will bring gene therapy for [insert disease] closer to the clinic, and we are looking forward to giving you more details during our presentation,” is a qualitative statement and preferred in the case of an exception. However, a statement such as “in the study submitted to ESGCT, 5 of 7 patients demonstrate no disease symptoms and we’ve applied for EMA fast track designation,” is a quantitative statement and should not be included in a release.